Sunday, January 23, 2005
The FTC's Bureau of Competition recently posted summaries of its FY 2004 settlements with pharmaceutical companies. Among the highlights:
1) 19 of the 22 agreements filed in FY 2004 involved agreements between brand and generic manufacturers, with the remainder occurring between two generic manufacturers;
2) 14 of these 19 agreements resolved patent infringement litigation between brand and generic manufacturers; and
3) no settlement included a payment from the brand to the generic manufacturer in exchange for the generic’s agreement not to market its product.